Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate

Neoplasma

Volumn 52, Issue 6, 2005, Pages 510-516

  Bodo, J ^a   Chovancova, J ^a   Hunakova, L ^a   Sedlak, J ^a  

^a Cancer Research Institute   (Slovakia)

Author keywords

Apoptosis; Cisplatin; Growth inhibition; Isothiocyanate; Ovarian carcinoma

Indexed keywords

CISPLATIN; ETHYL 4 ISOTHIOCYANATOBUTANOATE; ISOTHIOCYANIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RESISTANCE; CELL PROLIFERATION; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG INHIBITION; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; OVARY CARCINOMA;

EID: 29144494795     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. AGARWAL R, KAYE SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-516.
2. BAIRD RD, KAYE SB. Drug resistance reversal - are we getting closer? Eur J Cancer 2003; 39: 2450-2461.
3. BARTKOWIAK D, HOGNER S, BAUST H, NOTHDURFT W, ROTTINGER EM. Comparative analysis of apoptosis in HL60 detected by annexin-V and fluorescein-diacetate. Cytometry 1999; 37: 191-196.
4. CHIBA T, TAKAHASHI S, SATO N, ISHII S, KIKUCHI K. Fas-mediated apoptosis is modulated by intracellular glutathione in human T cells. Eur J Immunol 1996; 26: 1164-1169.
5. FIMOGNARI C, NUSSE M, BERTI F, IORI R, CANTELLI-FORTI G et al. Isothiocyanates as novel cytotoxic and cytostatic agents: molecular pathway on human transformed and non-transformed cells. Biochem Pharmacol 2004; 68: 1133-1138.
6. FLOCH L, KUBAN J, GOGOVA A, JAKUBIK T, PRONAYOVA N. Synthesis of ethyl 4-isothiocyanatobutanoate derivatives. Chem Pap -Chem Zvesti 1997; 51: 416-420.
7. HORAKOVA K, JANTOVA S, STREDANSKY M, NOVOTNA L, FLOCH L. Ethyl 4-isothiocyanatobutanoate - antiproliferative activity in-vitro and in-vivo. Anti-Cancer Drugs 1993; 4: 369-375.
8. HORAKOVA K, STRAKOVA Z, JANTOVA S, MUCKOVA M, FLOCH L. Biological effects of 2-isothiocyanate carboxylic-acid esters 1. Cyto-toxic, antimicrobial and genetoxic screening amino-acid isothiocyanate derivatives. Biologia 1989; 44: 637-646.
9. JAKUBIKOVA J, SEDLAK J, MITHEN R, BAO Y. Role of PI3K7Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G(2)/M arrest and cell death in Caco-2 cells. Biochem Pharmacol 2005; 69: 1543-1552.
10. JANSEN BAJ, BROUWER J, REEDIJK J. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J Inorg Biochem 2002; 89: 197-202.
11. KONG ANT, YU R, HEBBAR V, CHEN C, OWUOR E et al. Signal transduction events elicited by cancer prevention compounds. Mutat Res -Fundam Mol Mech Mutagen 2001; 480: 231-241.
12. MARKMAN M. Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer. Crit Rev Oncol Hematol 2001; 38: 171-175.
13. MICHAUD DS, SPIEGELMAN D, CLINTON SK, RIMM EB, WILLETT WC et al. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst 1999; 91: 605-613.
14. MOSMANN T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
15. PULLAR JM, THOMSON SJ, KING MJ, TURNBULL CI, MIDWINTER RG et al. The chemopreventive agent phenethyl isothiocyanate sensitizes cells to Fas-mediated apoptosis. Carcinogenesis 2004; 25: 765-772.
16. SAYED-AHMED MM, EISSAA MA, KENAWY SA, MOSTAFA N, CALVANI M et al. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy 2004; 50: 162-170.
17. SOVCIKOVA A, TULINSKA J, CHALUPA I, LISKOVA A, KURICOVA M et al. Immunotoxic and cancerostatic effects of ethyl-4-isothiocyanatobutanoate in female Lewis rats with implanted fibrosarcoma. Int Immunopharmacol 2002; 2: 1681-1691.
18. SVEHLIKOVA V, WANG SR, JAKUBIKOVA J, WILLIAMSON G, MITHEN R et al. Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA1 in CaCo-2 cells. Carcinogenesis 2004; 25: 1629-1637.
19. TULINSKA J, SOVCIKOVA A, LISKOVA A, KUBOVA J, HORAKOVA K. Immunotoxicity of ethyl-4-isothiocyanatobutanoate in male Wistar rats. Toxicology 2000; 145: 217-225.
20. VASILEVSKAYA IA, RAKITINA TV, O'DWYER PJ. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol 2004; 65: 235-243.
21. WERNYJ RP, MORIN PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Update 2004; 7: 227-232.
22. XIAO D, SRIVASTAVA SK, LEW KL, ZENG Y, HERSHBERGER P et al. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G(2)/M arrest and inducing apoptosis. Carcinogenesis 2003; 24: 891-897.
23. YU R, JIAO JJ, DUH JL, TAN TH, KONG ANT. Phenethyl isothiocyanate, a natural chemopreventive agent, activates c-Jun N-terminal kinase 1. Cancer Res 1996; 56: 2954-2959.
24. ZHANG YS, TALALAY P. Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic phase 2 enzymes. Cancer Res 1998; 58: 4632-4639.